

REMOVED: P57 NIMOTUZUMAB IN COMBINATION WITH DOCETAXEL AND CARBOPLATIN AS TREATMENT FOR ADVANCED NON-SMALL-CELL-LUNG-CANCER

D. Qi^a, Q. Wang^a, C. Huang^a, Y. Li^a, Y. Yang^a, Y. Cui^a, L. Xin^a, J. Xu^a, H. Wang^a, J. Zheng^{*,b,c}

^aKey Laboratory of Cancer Prevention and Therapy, Department of First-Class Ward, Cancer Hospital, Tianjin Medical University, Tianjin, China, ^bBiotech Pharmaceuticals Co. Ltd., China, ^cMedical School, Tongji University, Shanghai, China

This article has been removed: please see Elsevier Policy on Article Withdrawal (<http://www.elsevier.com/locate/withdrawalpolicy>).

This abstract has been removed at the request of the Editor-in-Chief and author because it contains a drug dosage error which could have serious health consequences. The abstract contained a dosage error for the drug, docetaxel.

The corrected abstract should read as follows:

Background: We evaluated the efficacy of nimotuzumab combined with docetaxel and carboplatin (TP) for treatment of advanced non-small-cell-lung-cancer (NSCLC), as well as the effect on circulating blood markers and patient's side-effects.

Methods: 21 patients with advanced NSCLC were enrolled in the study. Patients were given nimotuzumab (200 mg/week for 6 weeks) and DP regimen (60 mg/m² docetaxel and 400 mg/m² carboplatin, twice). Each patient had two cycles of chemotherapy. Response data was collected before and after treatment. Tumour size and reduction were recorded by thoracic CT scan and compared. Treatment related side-effects were compared by statistical methods.

Findings: Tumour size and levels of CEA, NSE, and CYFR21-1 were decreased after treatment ($p=0.01$, $p=0.02$, $p=0.03$). Four patients had a complete response, five had a partial response, nine had stable disease, and three had progressive disease. Three patients had side-effects on facial skin and were graded as stage I–II disease.

Interpretation: Nimotuzumab combined with DP regimen may increase the efficacy of treatment, with few side-effects.

Funding: Beijing Science Plan.

The authors declared no conflicts of interest.